Literature DB >> 19952879

Pregabalin-induced parkinsonism: a case report.

Santiago Perez Lloret1, Mariela Amaya, Marcelo Merello.   

Abstract

BACKGROUND: : Pregabalin (PGB) is an L-type, voltage-dependent, calcium-channel blocker, useful for the treatment of neuropathy pain and some forms of seizures. We report the case of a 64-year-old woman who developed full-blown parkinsonism after PGB administration. CASE REPORT: : A female patient who developed diabetic sensory-motor polyneuropathy began treatment with gabapentin 300 mg plus amitriptyline 25 mg at the age of 56 years, with good tolerance. Eight years later, PGB 150 mg was added, after 3 months she developed a parkinsonian-like syndrome with axial symptoms, bilateral symmetric postural tremor, bradykinesia, and rigidity in both upper and lower limbs. Unified Parkinson's Disease Rating Scale motor score was 27/108 points at this time. Clear link to PGB introduction as well as symmetric limb involvement and symptom intensity made us suspect drug-induced parkinsonism. Pregabalin was withdrawn. Six months later, the patient had almost completely recovered; her Unified Parkinson's Disease Rating Scale motor score dropped to 4/108; and 3 months after that, it was 0.
CONCLUSION: : Although some cases of tremor were reported in clinical trials on PGB, to our knowledge, this is the first report of full-blown parkinsonism associated with PGB use. Vigilance of PGB-treated patients is recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952879     DOI: 10.1097/WNF.0b013e3181a9eb1b

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

Review 1.  Therapies for Restless Legs in Parkinson's Disease.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2019-11-09       Impact factor: 3.598

2.  Pregabalin: a treatment option for dystonia?

Authors:  Christina Karosin; Markus Kofler; Andreas Mayr; Leopold Saltuari
Journal:  Neurol Sci       Date:  2011-08-18       Impact factor: 3.307

Review 3.  Antiseizure Drugs and Movement Disorders.

Authors:  Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano
Journal:  CNS Drugs       Date:  2022-07-21       Impact factor: 6.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.